ABT-863 / Abilita Therapeutics - LARVOL DELTA

ABT-863: The next generation anti-CCR8 immuno-oncology antibody therapeutic (AACR 2025) - "Because of its distinct pharmacology, this mechanism may offer more robust modulation of the TME and immune responses, potentially enhancing therapeutic efficacy, while avoiding unnecessary safety risks of depleting Tregs in healthy tissues or other CCR8-expressing cell types. In conclusion, ABT-863 is a differentiated first-in-class inverse agonist antibody with the potential to provide superior efficacy, improved safety and more favorable patient outcomes."

Immuno-oncology • IO biomarker • Colon Cancer • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • CCR8